Effectiveness of Olanzapine for the Treatment of
Breakthrough Chemotherapy Induced
Nausea and Vomiting
Suthan Chanthawong BPharm*,
Suphat Subongkot PharmD*, Aumkhae Sookprasert MD**
Affiliation :
* Division of Clinical Pharmacy, Faculty of Pharmaceutical Sciences, Khon Kaen University, Khon Kaen, Thailand
** Department of Internal Medicine, Faculty of Medicine, Khon Kaen University, Khon Kaen, Thailand
Objective : To evaluate safety and efficacy of olanzapine for breakthrough emesis in addition to standard antiemetic regimen
in cancer patients receiving highly emetogenic chemotherapy.
Material and Method: A phase II prospective open label clinical trial was conducted in tertiary care based hospital. Forty-six
cancer patients diagnosed with solid tumors were enrolled to receive at least one cycle of highly emetogenic chemotherapy
(HEC) every two to four weeks. Each patient was provided standard antiemetic consisting of the generic form of ondansetron
plus corticosteroids and metoclopramide according to clinical practice guideline. Olanzapine was administered as 5 mg
orally every 12 hours for two doses in patients experiencing breakthrough emesis for at least one episode despite standard
prevention. The efficacy and tolerability were evaluated every six hours for 24 hours (utilizing Index of Nausea, Vomiting
and Retching: INVR tool).
Results : Of 46 evaluable patients receiving HEC and additional olanzapine between September 2009 and July 2010, the
complete response of breakthrough emesis, retching, and nausea control among patients were 60.9%, 71.7%, and 50.0%,
respectively. Adverse events reported were mild and tolerable including dizziness, fatigue, and dyspepsia.
Conclusion : Olanzapine is considered to be safe and effective treatment of breakthrough vomiting in cancer patients
undergoing highly emetogenic chemotherapy in the present study.
Keywords : Olanzapine, Chemotherapy induced nausea and vomiting, Breakthrough vomiting, Ondansetron, Metoclopramide,
Dexamethasone
All Articles
Download